View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
December 14, 2018

Innovent reports positive results from two trials of IBI305

Innovent Biologics has reported positive results from two clinical trials of IBI305 after meeting the pre-defined primary endpoints of both studies.

Innovent Biologics has reported positive results from two clinical trials of IBI305 after meeting the pre-defined primary endpoints of both studies.

China-based Innovent’s IBI305 is a biosimilar of bevacizumab, which is a recombinant humanised anti-vascular endothelial growth factor (VEGF) monoclonal antibody developed for use as injection.

The CIBI305A301 and CIBI305A201 trials evaluated IBI305 in comparison with bevacizumab to treat advanced non-squamous non-small cell lung cancer (NSCLC), a type of epithelial lung cancer.

CIBI305A301 is a Phase III trial that evaluated the efficacy and safety of IBI305 and bevacizumab in patients with advanced non-squamous NSCLC.

“The current morbidity and mortality of malignant tumours in China are high, and anti-tumour treatment is a significant economic burden.”

The randomised, double-blinded, parallel, positive-controlled trial enrolled 450 patients and aims to compare the clinical activity and safety of IBI305 and bevacizumab in combination with paclitaxel / carboplatin.

Its primary endpoint includes objective response rate (ORR).

The CIBI305A201 trial intends to investigate the pharmacokinetic profile, safety, tolerability, and immunogenicity of IBI305 in comparison with bevacizumab.

A total of 100 subjects were included in the randomised, double-blinded, parallel, positive-controlled single-dose trial.

Primary endpoint of the trial is to compare the pharmacokinetic (PK) profile of IBI305 and bevacizumab.

Innovent Biologics founder, CEO and chairman Michael Yu said: “The current morbidity and mortality of malignant tumours in China are high, and anti-tumour treatment is a significant economic burden for millions of families.

“Anti-angiogenic drugs are effective anti-tumour treatments, but as of yet there are no approved bevacizumab biosimilars in China.

“The clinical studies of IBI305, a potential biosimilar of bevacizumab, are encouraging.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena